Apatinib
18
3
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
22%
4 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (18)
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Apatinib for Resectable Colorectal Cancer
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy
mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer
First-line Chemotherapy for Recurrent Cervical Cancer
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer
Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers
Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
Apatinib for Metastatic Esophageal Cancer.